Covid-2019:“A Microbiological Monster”
Asian Journal of Medicine and Health,
Pneumonia triggered by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a extremely contagious disease. The WHO has stated the outbreak of Covid 19(Corona virus) as a pandemic issue. Currently, the research on this virus is in its primary stage. Based on the existing and available data, this is to enlighten on the epidemiology, its clinical features, diagnosis, treatment and prevention of COVID-19. This review is for the public to effectively recognize and fight with the 2019 novel coronavirus and providing a spark for future studies.
- coronavirus disease 2019 (COVID-19)
How to Cite
Cavanagh D. Coronavirus avian infectious bronchitis virus. Vet Res. 2007;38:281–97.
Ismail MM, Tang AY, Saif YM. Pathogenicity of turkey coronavirus in turkeys and chickens. Avian Dis. 2003;47: 515–22.
Zhou P, Fan H, Lan T, Yang XL, Shi WF, Zhang W et al. Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. Nature. 2018; 556(7700):255–58.
Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med. 2004;10 (suppl 12):S88–97.
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20.
Lee J, Chowell G, Jung E. A dynamic compartmental model for the Middle East respiratory syndrome outbreak in the Republic of Korea: A retrospective analysis on control interventions and supers preading events. J TheorBiol. 2016; 408:118–26.
Lee JY, Kim YJ, Chung EH, Kim DW, Jeong I, Kim Y et al. The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015. BMC Infect Dis. 2017; 17:498.
Chen Y, Liu Q, Guo D. Emerging corona-viruses: Genome structure, replication, and pathogenesis. J MedVirol. 2020;92:418-423.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL; 2020.
Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020; 395(10224):e39. 5.
Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coron-avirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5): 2000062.
Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 [published online ahead of print, 2020 Mar 17].
Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9.
Cleveland JL, Gray SK, Harte JA, Robison VA, Moorman AC, Gooch BF. Trans-mission of blood-borne pathogens in US dental health care settings: 2016 update. J Am Dent Assoc. 2016;147(9): 729–738.
Coronavirus disease 2019 (COVID-19) Situation Report (WHO) – 63 Data as reported by national authorities by 10:00 CET 23 March 2020.
Ghinai I, McPherson TD, Hunter JC, et al.: First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA [Epub ahead of print]. Lancet; 2020.
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia [Epub ahead of print]. N Engl J Med; 2020.
Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol; 2020.
[Epub ahead of print]
Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist. Radiology. 2020;295:16-17.
Guo YR, Cao QD, Hong ZS, Tan YY,Chen SD, Jin HJ, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID 19) outbreak–an update on the status. Military Medical Research. 2020;7(1):1-10.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang Jet al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.
National Health Commission of the People’s Republic of China. Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version 6); 2020.
Chen L, Xiong J, Bao L, Shi Y. Con-valescent plasma as a potential therapy for COVID-19. Lancet Infect Dis; 2020.
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - Drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–47.
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221–18.
Holshue ML, DeBolt C, Lindquist S,Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med; 2020.
[Epub ahead of print].
Guiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 2018;8(3):459–64.
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today's diseases? Lancet Infect Dis. 2003; 3(11):722–7.
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: A novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res; 2020. [Epub ahead of print].
Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs. 2003;63(8):769– 802.
Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020; 21(1):8.
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59(3):252–6.
Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: The application of lopinavir/ ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6): e79.
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel corona virus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends; 2020.
[Epub ahead of print].
Abstract View: 843 times
PDF Download: 510 times